Therefore, we propose that TNFAIP3, a critical modulator of ZSH‐2208, may serve as a significant prognostic indicator for patients with ESCC and could also represent a potential target for anti‐tumour therapies. Here, TNFAIP3 is linked to esophageal squamous cell carcinoma.